Background:  Human leukocyte antigen A2 (HLA-A2) is a human class I histocompatibility (MHC I) molecule. MHC I molecules are integral parts of the immune response and present peptides on the cell surface to T lymphocytes (CTLs). HLA-A2 is associated with interferon-a therapy-induced autoimmune thyroid dysfunction in patients with chronic hepatitis C. In primary T cells, HIV evasion of the cellular immune response reveals that HLA-A2 antigens are downmodulated more dramatically than total MHC class I antigens. Downregulation of MHC class I HLA-A2 antigens occurs not only in primary T cells, but also in b and astrocytoma cell lines. Heavy chain modifications to HLA-A2 enhance the presentation of defined HIV-1 epitope-specific CTL target structures. Incorpo-ration of HIV-1 CTL epitopes into the signal sequence of HLA or tethering of epitopes to the HLA-A2 heavy chain provide simple ways to create effective CTL target structures which can be recognized and lysed by human HLA-A2 restricted RT-specific CD8+ CTL.

Description: Rabbit polyclonal to HLA-A2

Immunogen: KLH conjugated synthetic peptide derived from HLA-A2

Specificity:  ·Reacts with Human, Mouse and Rat.

·Isotype: IgG

Application:  ·Western blotting: 1/100-500;

·Immunohistochemistry (Paraffin/frozen tissue section): 1/50-200;

·Immunocytochemistry/Immunofluorescence: 1/100;

·Immunoprecipitation: 1/50;

·ELISA: 1/500;

·Optimal working dilutions must be determined by the end user.